Health-Related Quality of Life among Patients with Hepatitis C Virus Infection: A Cross-Sectional Study in Jianping County of Liaoning Province, China

Hairui Zhang,1 Ran Ren,2 Jinlin Liu,3 Ying Mao,3 Guowei Pan,4 Ke Men,1, and Li Ma2

1Institute for Research on Health Information and Technology, School of Public Health, Xi’an Medical University, Xi’an, Shaanxi 710021, China
2School of Public Health, Dalian Medical University, Dalian, Liaoning 116044, China
3School of Public Policy and Administration, Xi’an Jiaotong University, Xi’an, Shaanxi 710049, China
4Center for Disease Prevention and Control of Liaoning Province, Shenyang, Liaoning 110001, China

Correspondence should be addressed to Ke Men; menke@xiyi.edu.cn and Li Ma; mali@dlmedu.edu.cn

Received 22 October 2019; Accepted 26 December 2019; Published 7 January 2020

Academic Editor: Kazuhiko Uchiyama

Copyright © 2020 Hairui Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Patients with chronic liver disease (CLD) have extrahepatic manifestations and impaired health-related quality of life (HRQOL), and hepatitis C virus (HCV) infection is a leading cause of CLD, cirrhosis, and hepatocellular carcinoma (HCC). This study is aimed at assessing HRQOL in patients with HCV infection in the rural areas and identifying factors associated with impairment of HRQOL.

Methods. A cross-sectional study was conducted in a county of Liaoning Province in northeast China. HRQOL of patients with HCV infection was assessed using the chronic liver disease questionnaire (CLDQ) and EuroQol-5 dimensions (EQ-SD). Data were transformed to score comparisons of six major CLDQ domains, EQ index, and visual analog scale (VAS). Results. A total of 397 (93.4%) subjects, including 67 healthy subjects (HSs), 314 patients with chronic hepatitis C (CHC), and 16 patients with liver cirrhosis (LC) completed the study. The overall quartile CLDQ scores for HSs, patients with CHC, and patients with LC were 6.4 (6.0, 6.7), 5.8 (4.6, 6.4), and 4.1 (3.0, 6.0), respectively. The quartile scores of EQ index for the three groups were 1.0 (1.0, 1.0), 1.0 (0.8, 1.0), and 0.9 (0.6, 1.0), respectively. The median scores of EQ VAS for the three groups were 85.0, 60.0, and 60.0, respectively. Female sex, patients with family history of hepatitis, other comorbid chronic diseases, drinking, and disease duration ≥10 years were associated with significant improvement in overall CLDQ scores, and family history of hepatitis and other comorbid chronic diseases were considered predictive factors for EQ index and VAS, respectively. Conclusions. Compared with HSs, HCV infection had a greater negative impact on HRQOL in patients with CHC and LC. The significant factors associated with HRQOL include female sex, patients with a family history of hepatitis, other comorbid chronic diseases, drinking, and disease duration ≥10 years. Patients with HCV infection in the rural areas should be paid careful attention regarding their HRQOL with proper health education and disease management.

1. Introduction

Viral hepatitis ranks first among infectious diseases, and the chronic hepatitis C (CHC) has currently been considered the “invisible killer” of chronic hepatitis in China [1]. According to the recent data released by the World Health Organization, the global prevalence of HCV is 3%, and approximately 170 million people are infected with HCV, with the annual incidence of new cases being approximately 35,000 [2, 3]. Of these patients, 20%–30% progress into liver cirrhosis (LC) or hepatocellular carcinoma (HCC) [4]. However, the public, specifically individuals living in the rural areas, has insufficient knowledge on the route of transmission and the corresponding preventive measures for CHC.

Health-related quality of life (HRQOL), as an objective instrument for evaluating patients’ physical, psychological, and social adaptation and other indicators, has become significantly favorable to clinical doctors and health managers...
2. Materials and Methods

2.1. Patients. Since August 2014, to analyze the comprehensive prevention and treatment of CLD in Liaoning Province, the National Ministry of Science and Technology of China commissioned the Center for Disease Control and Prevention of Liaoning Province to complete the research. This study conducted an epidemiological screening in CLD research from August 2014 to June 2015. As a cross-sectional study, the convenient sampling method was used, subjects volunteered to participate in the survey, and the information was consecutively collected from patients with CHC, patients with LC, and the HSS. The diagnostic criteria of the disease were established following the standards in the guideline of prevention and therapy of hepatitis C, which was issued by the Hepatology Branch, Infectious Disease & Parasitologic Diseases Branch, Chinese Medical Association [8]. All patients were aged greater than 18 years who were infected with hepatitis C greater than 6 months. Patients were excluded if they had severe cognitive impairment, were coinfected with other types of hepatitis virus (hepatitis A virus, hepatitis B virus, hepatitis D virus, and hepatitis E virus), or refused to provide written informed consent. HSS were enrolled, and all subjects provided written informed consent for inclusion in the study.

Face-to-face interviews were conducted by well-trained interviewers and noninductive language was used for investigation. In order to protect the information of subjects, researchers cannot identify the information of each individual. Subjects’ sociodemographic characteristics, including age, gender, marital status (married or not married), education level (no schooling and primary, secondary, and tertiary), comorbidity chronic illness, family history of hepatitis, and disease duration, were collected. Meanwhile, subjects’ HRQOL was measured using the CLDQ and EQ-5D. The questionnaire will be excluded if the missing data exceeds 20% and above.

2.2. Questionnaires. The CLDQ is a standardized disease-specific HRQOL measurement for liver disease that is developed by Younossi et al. [9]. The questionnaire consists of 29 items that are divided into the following six domains: abdominal symptoms (AS), fatigue (FA), systemic symptoms (SS), activity (AC), emotional function (EF), and worry (WO). Each item is rated on a 7-point Likert scale ranging from 1 (all the time) to 7 (none of the time). The domain scores were calculated using the means of the items contained, and the overall score was the means of all item scores. In 2003, the CLDQ has been formally translated from the original version into Chinese version and was approved to be a reliable and valid questionnaire in assessing HRQOL in patients with CLDs [10].

EQ-5D is one of the most widely used generic scales that was presented by the EuroQol Group [11]. It consists of the following two parts: the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has the following three levels: no problems, some problems, and severe problems, which can be transformed to a single measure called EQ index or utility value. It ranges from 0 (reference value assigned to death) to 1 (perfect health), with the possibility of negative values for health status considered worse than death [12]. EQ VAS asks people to assess their own health status through a vertical thermometer-like scale ranging from 0 to 100, where 0 reflects the worst imaginable health status and 100 the best imaginable health status. Since the EQ-5D was developed, it has been widely used in measuring the HRQOL of special and normal in many counties [13, 14]. It showed a good reliability compared to other utility measures for both self and proxy ratings in people, making it therefore one of the most common instruments in evaluating HRQOL [15].

2.3. Statistical Analysis. Descriptive analysis for continuous variables was performed with mean ± standard deviation for normally distributed data and interquartile range and median for nonnormally distributed data. Categorical variables were described by counts and related percentages. Pearson’s chi-square test and Fisher’s exact test were used to compare the distribution of sociodemographic variables between all patients and the healthy subjects. Mann-Whitney U test was performed to compare the HRQOL score of each domain of CLDQ and EQ-5D among the three groups. Associations between variables were measured using Spearman’s correlation coefficient to examine the association between each domain of CLDQ and EQ-5D. Additionally, multivariate linear regression was performed to estimate independent association of each variable with the score of overall, EQ index, and VAS. All tests were two-sided with a significance level < 0.05. All data were double-typed with Epidata3.2 by two different persons to avoid data errors, and SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA) was used to conduct all the analysis.
3. Results

3.1. Subject Characteristics. All subjects were from rural areas in Jianping County, and a total of 425 subjects participated in the study, of which 28 were excluded because they did not complete the questionnaire. A total of 397 (93.4%) subjects, which included 67 HSs, 314 patients with CHC, and 16 patients with LC, completed the study, and the mean ages were 51.5 ± 9.5, 55.2 ± 8.2, and 60.4 ± 7.4 years, respectively. Greater than two-fifths (42.3%) were aged from 50 to 59 years old. A total of 67.5% of the subjects were female. Regarding marital status, most of the subjects (96.0%) were married and lived with their families; subsequently, the remaining subjects had no spouse (divorced, dead, or not married). As regards disease duration, 58.8% of the patients (CHC and LC) had disease duration greater than 5 years. Information about subject’s sociodemographic characteristics is summarized in Table 1.

| Characteristics                  | HSs (n = 67) | CHC (n = 314) | LC (n = 16) | P value |
|----------------------------------|-------------|---------------|-------------|---------|
| Age (years)                      |             |               |             | <0.001  |
| <50                              | 33 (49.3)   | 86 (27.4)     | 1 (6.3)     |         |
| 50-59                            | 23 (34.3)   | 140 (44.6)    | 5 (31.2)    |         |
| ≥60                              | 11 (16.4)   | 88 (28.0)     | 10 (62.5)   |         |
| Gender                           |             |               |             | 0.230   |
| Female                           | 43 (64.2)   | 217 (69.11)   | 8 (50.0)    |         |
| Male                             | 24 (35.8)   | 97 (30.89)    | 8 (50.0)    |         |
| BMI (kg/m²)                      |             |               |             | 0.251   |
| <18.5                            | 4 (6.0)     | 11 (3.5)      | 1 (6.3)     |         |
| 18.5-23.9                        | 46 (68.7)   | 188 (59.9)    | 11 (68.7)   |         |
| ≥24                              | 17 (25.3)   | 115 (36.6)    | 4 (25.0)    |         |
| Marital status                   |             |               |             | 0.332   |
| Married                          | 63 (94.0)   | 303 (96.50)   | 15 (93.7)   |         |
| No spouse¹                       | 4 (6.0)     | 11 (3.50)     | 1 (6.3)     |         |
| Education status                 |             |               |             | 0.001   |
| Primary school and below         | 24 (35.8)   | 179 (57.0)    | 13 (81.3)   |         |
| Junior school                    | 30 (44.8)   | 114 (36.3)    | 3 (18.7)    |         |
| Senior school and above          | 13 (19.4)   | 21 (6.7)      | 0 (0.0)     |         |
| Annual family income (Yuan)      |             |               |             | <0.001  |
| <10000                           | 7 (10.4)    | 70 (22.3)     | 5 (31.2)    |         |
| 10000-19999                      | 13 (19.4)   | 107 (34.1)    | 7 (43.8)    |         |
| 20000-29999                      | 11 (16.4)   | 70 (22.3)     | 2 (12.5)    |         |
| ≥30000                           | 36 (53.7)   | 67 (21.3)     | 2 (12.5)    |         |
| Other comorbid chronic diseases   |             |               |             | <0.001  |
| Yes                              | 1 (1.5)     | 116 (36.9)    | 3 (18.7)    |         |
| No                               | 66 (98.5)   | 198 (63.1)    | 13 (81.3)   |         |
| Family history of hepatitis      |             |               |             | <0.001  |
| Yes                              | 2 (3.0)     | 76 (24.2)     | 3 (18.7)    |         |
| No                               | 65 (97.0)   | 238 (75.8)    | 13 (81.3)   |         |
| Smoking status                   |             |               |             | 0.922   |
| Current smoker                   | 33 (49.3)   | 150 (47.8)    | 7 (43.7)    |         |
| Nonsmoker                        | 34 (50.7)   | 164 (52.2)    | 9 (56.3)    |         |
| Drinking status                  |             |               |             | 0.004   |
| Current drinker                  | 33 (49.3)   | 90 (28.7)     | 4 (25.0)    |         |
| Nondrinker                       | 34 (50.7)   | 224 (71.3)    | 12 (75.0)   |         |
| Disease duration (years)         |             |               |             | 0.806   |
| <5                               | /           | 128 (40.8)    | 8 (50.0)    |         |
| 5-9                              | /           | 80 (25.5)     | 3 (18.8)    |         |
| ≥10                              | /           | 106 (33.7)    | 5 (31.2)    |         |

The data are expressed as counts (percent); BMI: body mass index calculated as weight/height² (kg/m²); CHC: chronic hepatitis C; LC: liver cirrhosis; HSs: healthy subjects. ¹No spouse aspect includes single, divorced, and widowed.

3.1. Subject Characteristics. All subjects were from rural areas in Jianping County, and a total of 425 subjects participated in the study, of which 28 were excluded because they did not complete the questionnaire. A total of 397 (93.4%) subjects, which included 67 HSs, 314 patients with CHC, and 16 patients with LC, completed the study, and the mean ages were 51.5 ± 9.5, 55.2 ± 8.2, and 60.4 ± 7.4 years, respectively. Greater than two-fifths (42.3%) were aged from 50 to 59 years old. A total of 67.5% of the subjects were female. Regarding marital status, most of the subjects (96.0%) were married and lived with their families; subsequently, the remaining subjects had no spouse (divorced, dead, or not married). As regards disease duration, 58.8% of the patients (CHC and LC) had disease duration greater than 5 years. Information about subject’s sociodemographic characteristics is summarized in Table 1.
3.2. The HRQOL Score of CLDQ and EQ-5D. We calculated the CLDQ and EQ-5D scores for every domain according to the subject’s specific response using the computational formula that is commonly used in Table 2. Except for patients with LC who had a normal distribution of scores in all domains, the scores of the other groups in each domain showed nonnormal distribution. The overall quartile CLDQ scores for HSs, patients with CHC, and patients with LC were 85.0, 60.0, and 60.0, respectively. Using the EQ index, subjects scored 1.0 for HSs, 1.0 for CHC vs. LC, and similar results were observed in patients with LC who had a normal distribution of scores in all domains, the scores of the other groups in each domain showed nonnormal distribution. The overall quartile CLDQ scores for HSs, patients with CHC, and patients with LC were 85.0, 60.0, and 60.0, respectively. Using the Mann-Whitney test, all the domain CLDQ and EQ-5D scores were significantly lower in patients with CHC than that in HSs, and similar results were observed in patients with LC and HSs. The median scores of the patients with CHC were significantly higher for FA, SS, AC, EF, WO, and overall CLDQ, except for AS, WO, and EQ-5D, compared to that of patients with LC.

3.3. The Correlation between CLDQ and ED-5D. All CLDQ domains were significantly associated with all the scores of EQ-5D subscales ($r > 0.408$, $P < 0.001$); the associations between the overall score and each domain score using the EQ index and EQ VAS ranged from weak to moderate in Table 3. The overall score was highly associated with the six domains, and the associations between WO and other domains were the lowest. Compared to the EQ index, EQ VAS had a week association with the overall and each domain score of CLDQ. Compared to the six domains, the strongest association was observed between the overall score of the CLDQ and all EQ-5D domains, followed by the associations between the overall score and each domain score using the EQ index, and VAS.

3.4. Independent Predictors of HRQL Scores. Multivariate linear regression analysis predicted the overall CLDQ scores, EQ index, and VAS. Table 4 shows the beta coefficients (95% confidence interval (CI)) obtained from each independent variable, which accounted for in the regression model. Regression analysis showed that female sex ($\beta = 0.435$; 95% CI, 0.084 to 0.786), patients with family history of hepatitis ($\beta = -0.406$; 95% CI, -0.723 to -0.088), other comorbid chronic diseases ($\beta = -0.300$; 95% CI, -0.585 to -0.014), drinking ($\beta = -0.347$; 95% CI, -0.677 to -0.017), and disease duration $\geq 10$ years ($\beta = -0.518$; 95% CI, -0.826 to -0.211) were predictive factors of overall CLDQ scores.

### Table 2: CLDQ and EQ-5D scores among patients with CHC, LC, and healthy subjects.

| Domain              | HSs  | CHC  | LC   | P*  | P** | P*** |
|---------------------|------|------|------|-----|-----|------|
| CLDQ                |      |      |      |     |     |      |
| Abdominal symptoms  | 6.7  | 6.3  | 5.0  | 0.006 | 0.004 | 0.053 |
| Fatigue             | 6.2  | 5.6  | 3.9  | 0.012 | 0.001 | 0.019 |
| Systemic symptoms   | 6.2  | 5.6  | 3.4  | <0.001 | <0.001 | 0.001 |
| Activity            | 6.7  | 5.7  | 4.0  | <0.001 | 0.001 | 0.035 |
| Emotional function  | 6.5  | 5.7  | 3.9  | <0.001 | <0.001 | 0.010 |
| Worry               | 7.0  | 6.3  | 5.2  | <0.001 | 0.003 | 0.281 |
| Overall             | 6.4  | 5.8  | 4.1  | <0.001 | <0.001 | 0.008 |
| EQ-5D               |      |      |      |     |     |      |
| Index               | 1.0  | 1.0  | 0.9  | 0.001 | 0.003 | 0.138 |
| VAS                 | 85.0 | 60.0 | 60.0 | <0.001 | 0.001 | 0.318 |

The data are expressed as median (interquartile range). CHC: chronic hepatitis C; LC: liver cirrhosis; HSs: healthy subjects; CLDQ: chronic liver disease questionnaire; EQ-5D: EuroQol-5D; VAS: visual analogue scale. *HS vs. CHC, **HS vs. LC, and ***CHC vs. LC.

### Table 3: Spearman’s correlation coefficients between CLDQ and EQ-5D domains.

| Domains        | AS   | FA   | SS   | AC   | EF   | WO   | Overall | Index | VAS   |
|----------------|------|------|------|------|------|------|---------|-------|-------|
| CLDQ           |      |      |      |      |      |      |         |       |       |
| Abdominal symptoms | 0.608* |      |      |      |      |      |         |       |       |
| Fatigue        | 0.634* | 0.690* |      |      |      |      |         |       |       |
| Systemic symptoms | 0.598* | 0.734* | 0.651* |      |      |      |         |       |       |
| Activity       | 0.618* | 0.731* | 0.685* | 0.696* |      |      |         |       |       |
| Emotional function | 0.469* | 0.558* | 0.524* | 0.552* | 0.662* |      |         |       |       |
| Worry          | 0.736* | 0.876* | 0.831* | 0.812* | 0.912* | 0.743* |         |       |       |
| Overall        | 0.528* | 0.643* | 0.629* | 0.591* | 0.624* | 0.499* | 0.694* |       |       |
| VAS            | 0.408* | 0.523* | 0.535* | 0.489* | 0.580* | 0.479* | 0.618* | 0.508* |       |

AS: abdominal symptoms; FA: fatigue; SS: systemic symptoms; AC: activity; EF: emotional function; WO: worry; VAS: visual analogue scale; CLDQ: chronic liver disease questionnaire; EQ-5D: EuroQol-5D. *Association is significant at the 0.01 level (2-tailed).
Notably, independent factors for EQ index and VAS were not similar to that of overall CLDQ scores. As shown in Table 4, patients with family history of hepatitis (β = -0.056; 95% CI, -0.104 to -0.008) were a predictive factor for EQ index, and other comorbid chronic diseases (β = -0.056; 95% CI, -0.104 to -0.008) were predictive factor for EQ VAS.

### 4. Discussion

Using the EQ-5D and CLDQ simultaneously is the most promising approach to evaluate the HRQOL of patients with HCV infection in the present study. Compared to the generic scale, the disease specificity scale can more accurately express the specific clinical symptoms of patients [16]. We found that the HRQOL in patients with HCV infection was significantly impaired in all domains compared to that of HSs, signifying that chronic viral hepatitis is more commonly seen in the rural areas than the urban areas of China and that the chronic sequelae of chronic viral hepatitis, such as cirrhosis and HCC, may have greatly affected patients’ health. We propose that patients with HCV infection in the rural areas should be paid careful attention regarding their HRQOL with proper health education and disease management [17].

A recent study, which was conducted using the Japanese version of the CLDQ among Japanese patients with chronic viral hepatitis, in Japan has reported that the CLDQ scores of these patients were lower compared to that of the present study except for the AC domain [18]. The median scores of the domains were as follows: AS with 6.3, FA with 5.6, SS with 5.6, AC with 5.7, EF with 5.7, WO with 6.3, and overall with 5.8. Scores of all CLDQ domains were significantly lower in patients with CHC than that in HSs, and similar results were observed in patients with LC and HSs in this study. According to the other studies, HCV elimination improves HRQOL in patients with CHC [19].

Some studies reported that psychiatric disorders, FA, and depression are common symptoms of HCV patients, which may constitute a major influencing factor for patients with low QOL [20, 21]. In the present study, the scores of FA and EF domains of CLDQ were relatively low among the six domains.

Notably, independent factors for EQ index and VAS were not similar to that of overall CLDQ scores. As shown in Table 4, patients with family history of hepatitis (β = -0.056; 95% CI, -0.104 to -0.008) were a predictive factor for EQ index, and other comorbid chronic diseases (β = -0.056; 95% CI, -0.104 to -0.008) were predictive factor for EQ VAS.

### Table 4: Multivariate linear regression for predictive factors on the overall CLDQ scores and EQ-5D in patients with HCV infection (CHC and LC).

| Variables                        | Overall CLDQ |                 | EQ index |                 | EQ VAS |                 |
|----------------------------------|--------------|----------------|----------|----------------|--------|----------------|
|                                  | β coefficient (95% CI) | P value | β coefficient (95% CI) | P value | β coefficient (95% CI) | P value |
| Gender                           |              |              |          |                |        |                |
| Male                             | 1            | 1             | 1        | 1              |        |                |
| Female                           | 0.435 (0.084 to 0.786) | 0.015 | 0.049 (-0.003 to 0.102) | 0.066 | 3.696 (-0.807 to 8.199) | 0.107 |
| Marital status                   |              |              |          |                |        |                |
| No spouse                        | 1            | 1             | 1        | 1              |        |                |
| Married                          | -0.205 (-0.924 to 0.515) | 0.576 | -0.009 (-0.117 to 0.099) | 0.869 | -3.104 (-12.306 to 6.098) | 0.507 |
| Family history of hepatitis      |              |              |          |                |        |                |
| No                               | 1            | 1             | 1        | 1              |        |                |
| Yes                              | -0.406 (-0.723 to -0.088) | 0.013 | -0.056 (-0.104 to -0.008) | 0.022 | -0.328 (-4.404 to 3.748) | 0.874 |
| Other comorbid chronic diseases  |              |              |          |                |        |                |
| No                               | 1            | 1             | 1        | 1              |        |                |
| Yes                              | -0.300 (-0.585 to -0.014) | 0.040 | -0.030 (-0.073 to 0.013) | 0.175 | -5.857 (-9.521 to -2.193) | 0.002 |
| Smoking status                   |              |              |          |                |        |                |
| No                               | 1            | 1             | 1        | 1              |        |                |
| Yes                              | -0.099 (-0.436 to 0.238) | 0.564 | -0.015 (-0.066 to 0.036) | 0.564 | -0.344 (-4.672 to 3.983) | 0.876 |
| Drinking status (years)          |              |              |          |                |        |                |
| No                               | 1            | 1             | 1        | 1              |        |                |
| Yes                              | -0.347 (-0.677 to -0.017) | 0.040 | -0.023 (-0.073 to 0.026) | 0.355 | -3.416 (-7.650 to 0.817) | 0.113 |
| Disease duration (years)         |              |              |          |                |        |                |
| <5                               | 1            | /             | /        | /              |        |                |
| ≥10                              | -0.518 (-0.826 to -0.211) | 0.001 | /              | /        |                |

VAS: visual analogue scale; CLDQ: chronic liver disease questionnaire; EQ-5D: European quality of life questionnaire-5 dimensions.
The results from generic questionnaire EQ-5D and disease-specific questionnaire CLDQ were in agreement with the fact that a marked decrease of QOL was observed in patients with HCV in this study. All EQ-5D domain scores were significantly lower in patients with HCV than that in HSs. The median EQ indices of patients with CHC and LC were 1.0 and 0.9, which were higher than that in Spain. EQ VAS of patients in the two groups was 60.0, which was lower than that in Spain [26].

Significant association between scores on EQ-5D subscales and CLDQ domains was observed. Overall CLDQ scores were highly associated with the six domains, and the associations between WO and other domains were the lowest. Compared to the EQ index, EQ VAS had a lower association with each domain of the CLDQ, and the results were consistent with the previous report [27]. The highly significant association between CLDQ and EQ-5D subscales provides further evidence for the convergent and discriminant validity of the CLDQ. Although CLDQ and EQ-5D do not define disease statuses, our study showed that these two methods could successfully represent the impaired HRQOL in patients with HCV.

Multivariate linear regression was performed to confirm the effect of variables on CLDQ and EQ-5D scores while controlling the influence of other variables. Regression analysis showed that female sex, patients with family history of hepatitis, other comorbid chronic diseases, drinking, and disease duration ≥ 10 years were the predictive factors of overall CLDQ scores. We found out that female sex had negative influence on HRQOL. Similarly, findings from a study in Thailand revealed that females have more health concerns and are more treatment-seekers than males [28]. Takahashi et al. reported that comorbid diseases such as primary biliary cholangitis may influence the HRQOL in patient with hepatitis [18]. This may be due to the fact that patients with CHC were originally unhealthy and had concurrent CLD; hence, the physiological function of the body would be significantly influenced. Regarding patients with family history of hepatitis, one possible explanation was that patients with the family history might be seriously affected by the family members both in physiological and in psychological aspects [19]. Compared to never drinker, regular drinker was also associated with worse CLDQ scores. Similarly, regarding disease duration, this factor was also negatively associated with CLDQ scores [18]. In this study, only patients with family history of hepatitis and other comorbid chronic diseases were predictive factors for EQ index and VAS, respectively. Despite the observed significant association between EQ-5D and CLDQ and the damage caused by liver disease in terms of specific performance of QOL, EQ-5D was not as sensitive as CLDQ [27].

5. Conclusions

Compared with HSs, HCV infection had a greater negative impact on HRQOL in patients with CHC and LC. The significant factors associated with HRQOL include female sex, patients with a family history of hepatitis, other comorbid chronic diseases, drinking, and disease duration ≥ 10 years. Patients with HCV infection in the rural areas should be paid careful attention regarding their HRQOL with proper health education and disease management.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This research was funded by the Ministry of Science and Technology of the People’s Republic of China (2013GS210102). In addition, the work was partially supported by the National Natural Science Foundation of China (Grant No. 81773496) and the National Social Science Fund of China (Grant No. 17ZDA079).

References

[1] A. Petruzzello, S. Marigliano, G. Loquercio, A. Cozzolino, and C. Cacciapuoti, “Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes,” *World Journal of Gastroenterology*, vol. 22, no. 34, pp. 7824–7840, 2016.

[2] Q. Qin, M. K. Smith, L. Wang et al., “Hepatitis C virus infection in China: an emerging public health issue,” *Journal of Viral Hepatitis*, vol. 22, no. 3, pp. 238–244, 2015.

[3] N. Coppola, L. Alessio, L. Onorato et al., “Epidemiology and management of hepatitis C virus infections in immigrant populations,” *Infectious Diseases of Poverty*, vol. 8, no. 1, p. 17, 2019.

[4] E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, “Global epidemiology and genotype distribution of the hepatitis C virus infection,” *Journal of Hepatology*, vol. 61, 1 Suppl, pp. S45–S57, 2014.

[5] C. Marinelli, E. Savarino, M. Inferrera et al., “Factors influencing disability and quality of life during treatment: a cross-sectional study on IBD patients,” *Gastroenterology Research and Practice*, vol. 2019, Article ID 5354320, 10 pages, 2019.

[6] Z. M. Younossi and L. Henry, “Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens,” *Alimentary Pharmacology & Therapeutics*, vol. 41, no. 6, pp. 497–520, 2015.

[7] J. E. Ware Jr., M. S. Bayliss, M. Mannocchia, and G. L. Davis, “Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group,” *Hepatology*, vol. 30, no. 2, pp. 550–555, 1999.

[8] Z. Yang, L. Zhuang, L. Yang et al., “Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis,” *Clinics and Research in Hepatology and Gastroenterology*, vol. 38, no. 4, pp. 440–450, 2014.

[9] Z. M. Younossi, G. Guyatt, M. Kiwi, N. Boparai, and D. King, “Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease,” *Gut*, vol. 45, no. 2, pp. 295–300, 1999.
[10] L. N. Ferreira, P. L. Ferreira, L. N. Pereira, and M. Oppe, “Psychometrics of chronic liver disease questionnaire in Chinese chronic hepatitis B patients,” *World Journal of Gastroenterology*, vol. 19, no. 22, pp. 3494–3501, 2013.

[11] E. S. Jang, Y. S. Kim, K. A. Kim et al., “Factors associated with health-related quality of life in Korean patients with chronic hepatitis C infection using the SF-36 and EQ-5D,” *Gut and Liver*, vol. 12, no. 4, pp. 440–448, 2018.

[12] EuroQol Group, “EuroQol—a new facility for the measurement of health-related quality of life,” *Health Policy*, vol. 16, no. 3, pp. 199–208, 1990.

[13] L. N. Ferreira, P. L. Ferreira, L. N. Pereira, and M. Oppe, “The valuation of the EQ-5D in Portugal,” *Quality of Life Research*, vol. 23, no. 2, pp. 413–423, 2014.

[14] S. Bernert, A. Fernández, J. M. Haro et al., “Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries,” *Value in Health*, vol. 12, no. 5, pp. 750–758, 2009.

[15] E. I. Lubetkin, H. Jia, and M. R. Gold, “Construct validity of the EQ-5D in low-income Chinese American primary care patients,” *Quality of Life Research*, vol. 13, no. 8, pp. 1459–1468, 2004.

[16] R.-M. Satherley, R. Howard, and S. Higgs, “Development and validation of the coeliac disease food attitudes and behaviours scale,” *Gastroenterology Research and Practice*, vol. 2018, Article ID 6930269, 9 pages, 2018.

[17] S. C. Kang, S. J. Hwang, S. H. Lee, F. Y. Chang, and S. D. Lee, “Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan,” *World Journal of Gastroenterology*, vol. 11, no. 47, pp. 7494–7498, 2005.

[18] A. Takahashi, K. Moriya, H. Ohira et al., “Health-related quality of life in patients with autoimmune hepatitis: a questionnaire survey,” *PLoS One*, vol. 13, no. 10, p. e0204772, 2018.

[19] Z. M. Younossi, M. Stepanova, S. Pol, J. P. Bronowicki, M. P. Carrieri, and M. Bourlière, “The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study,” *Liver International*, vol. 36, no. 1, pp. 42–48, 2016.

[20] B. C. Fábregas, R. E. de Ávila, M. N. Faria, A. S. Moura, R. A. Carmo, and A. L. Teixeira, “Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants,” *The Brazilian Journal of Infectious Diseases*, vol. 17, no. 6, pp. 633–639, 2013.

[21] I. M. Jacobson, P. Cacoub, L. D. Maso, S. A. Harrison, and Z. M. Younossi, “Manifestations of chronic hepatitis C virus infection beyond the liver,” *Clinical Gastroenterology and Hepatology*, vol. 8, no. 12, pp. 1017–1029, 2010.

[22] S. Mathias, R. D. Crosby, M. S. Bayliss, G. L’Italien, and S. Sapra, “Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary,” *Quality of Life Research*, vol. 23, no. 5, pp. 1489–1496, 2014.

[23] A. A. Dan, L. M. Martin, C. Crone et al., “Depression, anemia and health-related quality of life in chronic hepatitis C,” *Journal of Hepatology*, vol. 44, no. 3, pp. 491–498, 2006.

[24] A. Rei, M. Rocha, and I. Pedroto, “Health-related quality of life in Portuguese patients with chronic hepatitis C,” *GE Portuguese Journal of Gastroenterology*, vol. 24, no. 2, pp. 68–78, 2017.

[25] R. Huang, H. Rao, J. Shang et al., “A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis C virus infection with EQ-5D,” *Health and Quality of Life Outcomes*, vol. 16, no. 1, p. 124, 2018.

[26] R. Juanbeltz, I. Martinez-Baz, R. San Miguel, S. Goñi-Esarte, J. M. Cabasés, and J. Castilla, “Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients,” *PLoS One*, vol. 13, no. 10, p. e0205277, 2018.

[27] Y. H. Che, J. You, V. Chongsuvivatwong et al., “Dynamics and liver disease specific aspects of quality of life among patients with chronic liver disease in Yunnan, China,” *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 12, pp. 4765–4771, 2014.

[28] A. Sobhonslidsuk, C. Silpakit, R. Kongsakon, P. Satitpornkul, C. Sriptetch, and A. Khanthavit, “Factors influencing health-related quality of life in chronic liver disease,” *World Journal of Gastroenterology*, vol. 48, no. 48, pp. 7786–7791, 2006.